Entecavir

Source: Wikipedia, the free encyclopedia.
Entecavir
Clinical data
Pronunciation/ɛnˈtɛkəvɪər/ en-TEK-ə-veer
Trade namesBaraclude, others
Other namesBMS-200475-01
AHFS/Drugs.comMonograph
MedlinePlusa605028
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • UK: POM (Prescription only)
  • US: WARNING[2]Rx-only[3]
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailabilityn/a (≥70)[3]
Protein binding13% (in vitro)
Metabolismnegligible/nil
Elimination half-life128–149 hours
ExcretionKidney 62–73%
Identifiers
  • 2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one
JSmol)
Melting point220 °C (428 °F) value applies to entecavir monohydrate and is a minimum value[4]
  • C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N
  • InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1 ☒N
  • Key:QDGZDCVAUDNJFG-FXQIFTODSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Entecavir (ETV), sold under the brand name Baraclude, is an

antiretroviral medication should also be used.[5] Entecavir is taken by mouth as a tablet or solution.[5]

Common side effects include headache, nausea,

nucleoside reverse transcriptase inhibitors (NRTIs) family of medications.[5][6] It prevents the hepatitis B virus from multiplying by blocking reverse transcriptase.[5]

Entecavir was approved for medical use in 2005.[5] It is on the World Health Organization's List of Essential Medicines.[7] Available as a generic medication in the United States.

Medical uses

Entecavir is mainly used to treat chronic hepatitis B infection in adults and children two years and older with active viral replication and evidence of active disease with elevations in liver enzymes.[3] It is also used to prevent HBV reinfection after liver transplant[8] and to treat HIV patients infected with HBV. Entecavir is weakly active against HIV, but is not recommended for use in HIV-HBV co-infected patients without a fully suppressive anti-HIV regimen[9] as it may select for resistance to lamivudine and emtricitabine in HIV.[10]

The efficacy of entecavir has been studied in several randomized, double-blind, multicentre trials. Entecavir by mouth is effective and generally well tolerated treatment.[11]

Pregnancy and breastfeeding

No adequate and well-controlled studies exist in pregnant women.[1]

Side effects

The majority of people who use entecavir have little to no side effects.[12] The most common side effects include headache, fatigue, dizziness, and nausea.[3] Less common effects include trouble sleeping and gastrointestinal symptoms such as sour stomach, diarrhea, and vomiting.[13]

Serious side effects from entecavir include lactic acidosis, liver problems, liver enlargement, and fat in the liver.[3]

Laboratory tests may show an increase in alanine transaminase (ALT), hematuria, glycosuria, and an increase in lipase.[3] Periodic monitoring of hepatic function and hematology are recommended.[3]

Mechanism of action

Entecavir is a

tenofovir
.

Entecavir reduces the amount of HBV in the blood by reducing its ability to multiply and infect new cells.[15]

Administration

Entecavir is taken by mouth as a tablet or solution. Doses are based on a person's weight.[3] The solution is recommended for children more than 2 years old who weigh up to 30 kg. Entecavir is recommended on an empty stomach at least 2 hours before or after a meal, generally at the same time every day. It is not used in children less than 2 years old. Dose adjustments are also recommended for people with decreased kidney function.[3]

History

  • 1992: SQ-34676 at Squibb as part of anti-herpes virus program[16]
  • 1997: BMS 200475 developed at BMS pharmaceutical research institute as antiviral nucleoside analogue à Activity demonstrated against HBV, HSV-1, HCMV, VZV in cell lines & no or little activity against HIV or influenza[17]
  • Superior activity observed against HBV pushed research towards BMS 200475, its base analogues and its enantiomer against HBV in HepG2.2.15 cell line[17]
  • Comparison to other NAs, proven more selective potent inhibitor of HBV by virtue of being Guanine NA[18]
  • 1998: Inhibition of hepadnaviral polymerases was demonstrated in vitro in comparison to a number of NAs-TP[19]
  • Metabolic studies showed more efficient phosphorylation to triphosphate active form[20]
  • 3-year treatment of woodchuck model of CHB à sustained antiviral efficacy and prolonged life spans without detectable emergence of resistance[21]
  • Efficacy # LVD resistant HBV replication in vitro[22]
  • Superior activity compared to LVD in vivo for both HBeAg+ & HBeAg− patients[23][24]
  • Efficacy in LVD refractory CHB patients[25]
  • Entecavir was approved by the U.S. Food and Drug Administration (FDA) in March 2005.[26]

Patent information

Bristol-Myers Squibb was the original patent holder for Baraclude, the brand name of entecavir in the US and Canada. The drug patent expiration for Baraclude was in 2015.[27][28]
Entecavir patents were a subject of litigation in the US between
US Court of Appeals for the Federal Circuit
(752 F.32d 967).

On August 26, 2014,

Hetero Labs received such approval on August 21, 2015;[30] and Aurobindo Pharma on August 26, 2015.[31]

References

  1. ^ a b c "Entecavir (Baraclude) Use During Pregnancy". Drugs.com. 3 December 2019. Retrieved 24 January 2021.
  2. FDA
    . Retrieved 22 Oct 2023.
  3. ^ a b c d e f g h i "Baraclude- entecavir tablet, film coated Baraclude- entecavir solution". DailyMed. Retrieved 24 January 2021.
  4. ISBN 978-0-911910-00-1
    .
  5. ^ a b c d e f g h "Entecavir". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 28 November 2016.
  6. ISBN 9781597455657
    .
  7. hdl:10665/325771
    . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. PMID 21762659
    .
  9. ^ "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents" (PDF). Panel on Antiretroviral Guidelines for Adults and Adolescents. Archived (PDF) from the original on 1 November 2016. Retrieved 15 March 2015.
  10. PMID 17582071
    .
  11. S2CID 115493805. Archived from the original
    on 2011-10-08. Retrieved 2010-03-29.
  12. ^ "Entecavir: Indications, Side Effects, Warnings - Drugs.com". www.drugs.com. Archived from the original on 2016-11-07. Retrieved 2016-11-10.
  13. ^ "Entecavir Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 2016-11-10. Retrieved 2016-11-10.
  14. S2CID 13149070
    .
  15. ^ "Entecavir: Indications, Side Effects, Warnings - Drugs.com". www.drugs.com. Archived from the original on 2016-11-07. Retrieved 2016-11-07.
  16. doi:10.1016/0166-3542(92)90200-o
    .
  17. ^
    doi:10.1016/s0960-894x(96)00594-x
    .
  18. PMID 9210663
    .
  19. PMID 9835515
    .
  20. PMID 9869593
    .
  21. PMID 11679911
    .
  22. PMID 12121928
    .
  23. PMID 16525137
    .
  24. PMID 16525138
    .
  25. PMID 16762627
    .
  26. ^ "Drug Approval Package: Baraclude (Entecavir) NDA #021797 & 021798". U.S. Food and Drug Administration (FDA). 28 December 2011. Retrieved 24 January 2021.
  27. ^ "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". U.S. Food and Drug Administration (FDA). Archived from the original on 4 March 2016. Retrieved 2015-08-29.
  28. ^ "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". U.S. Food and Drug Administration (FDA). Archived from the original on 15 November 2016. Retrieved 14 November 2016.{{cite web}}: CS1 maint: unfit URL (link)
  29. ^ "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". U.S. Food and Drug Administration (FDA). Search results from the "OB_Rx" table for query on "202122.". Archived from the original on 22 December 2015. Retrieved 2015-08-29.
  30. ^ "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". U.S. Food and Drug Administration (FDA). Search results from the "OB_Rx" table for query on "205740.". Archived from the original on 4 March 2016. Retrieved 2015-08-29.
  31. ^ "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". U.S. Food and Drug Administration (FDA). Search results from the "OB_Rx" table for query on "206217.". Archived from the original on 4 March 2016. Retrieved 2015-08-29.

External links

  • "Entecavir". Drug Information Portal. U.S. National Library of Medicine.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Entecavir&oldid=1211984169"